-
Focus on myeloproliferative diseases and myelodysplastic syndromes.
Molecular Oncology Research Institute, Tufts-New England Medical Center, Boston, MA 02111, USA. rvanetten@tufts-nemc.org
PMID: 15607959 [PubMed - indexed for MEDLINE]
-
Cited by 10 PubMed Central articles
-
Oncogenic Kras initiates leukemia in hematopoietic stem cells.
Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS.
PLoS Biol. 2009 Mar 17; 7(3):e59.
[PLoS Biol. 2009]
-
Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease.
Ko J, Patel N, Ikawa T, Kawamoto H, Frank O, Rivera RR, Van Etten RA, Murre C.
Proc Natl Acad Sci U S A. 2008 Sep 2; 105(35):12967-72. Epub 2008 Aug 25.
[Proc Natl Acad Sci U S A. 2008]
-
Cdc42 critically regulates the balance between myelopoiesis and erythropoiesis.
Yang L, Wang L, Kalfa TA, Cancelas JA, Shang X, Pushkaran S, Mo J, Williams DA, Zheng Y.
Blood. 2007 Dec 1; 110(12):3853-61. Epub 2007 Aug 16.
[Blood. 2007]
- » See all...